- 1 COVID-19 cases from the first local outbreak of SARS-CoV-2 B.1.1.7 variant in
- 2 China presented more serious clinical features: a prospective, comparative cohort
- 3 study

9

15

16

20

21

- 5 Yang Song<sup>2\*</sup>, Ziruo Ge<sup>1\*</sup>, Shuping Cui<sup>1, 3\*</sup>, Di Tian<sup>1</sup>, Gang Wan<sup>1</sup>, Shuangli Zhu<sup>2</sup>,
- 6 Xianbo Wang<sup>1</sup>, Yu Wang<sup>1</sup>, Xiang Zhao<sup>2</sup>, Pan Xiang<sup>1</sup>, Yanli Xu<sup>1</sup>, Tingyu Zhang<sup>1</sup>, Long
- 7 Liu<sup>1</sup>, Gang Liu<sup>1</sup>, Yanhai Wang<sup>2</sup>, Jianbo Tan<sup>1</sup>, Wei Zhang<sup>1#</sup>, Wenbo Xu<sup>2#</sup>, and Zhihai
- 8 Chen<sup>1#</sup>
- <sup>1</sup>Emergency department of COVID-19, Beijing Ditan Hospital, Capital Medical
- 11 University, Beijing, China.
- <sup>2</sup> National Institute for Viral Disease Control and Prevention, Chinese Center for
- Disease Control and Prevention, Beijing, China.
- <sup>3</sup> Peking University, Ditan Teaching Hospital, Beijing, China.
- \*Yang Song, Ziruo Ge ,and Shuping Cui contributed equally to this paper.
- #Co-corresponding authors: Zhihai Chen, E-mail: chenzhihai0001@126.com; Wenbo
- 19 Xu, E-mail: xuwb@ivdc.chinacdc.cn; Wei Zhang, E-mail: snowpine12@sina.com

**Summary** 23 Background: The SARS-CoV-2 B.1.1.7 variant which was first identified in the United 24 Kingdom (U.K.) has increased sharply in numbers worldwide and was reported to be 25 more contagious. On January 17, 2021, a COVID-19 clustered outbreak caused by 26 B.1.1.7 variant occurred in a community in Daxing District, Beijing, China. Three 27 weeks prior, another non-variant (lineage B.1.470) COVID-19 outbreak occurred in 28 Shunyi District, Beijing. This study aimed to investigate the clinical features of B.1.1.7 29 variant infection. 30 Methods: A prospective cohort study was conducted on COVID-19 cases admitted to 31 Ditan hospital since January 2020. Data of 74 COVID-19 cases from two independent 32 COVID-19 outbreaks in Beijing were extracted as study subjects from a Cloud Database 33 established in Ditan hospital, which included 41 Shunyi cases (Shunyi B.1.470 group) 34 and 33 Daxing cases (Daxing B.1.1.7 group) that have been hospitalized since 35 December 25, 2020 and January 17, 2021, respectively. We conducted a comparison of 36 the clinical characteristics, RT-qPCR results and genomic features between the two 37 groups. 38 Findings: Cases from Daxing B.1.1.7 group (15 [45.5%] male; median age, 39 years 39 [range, 30.5, 62.5]) and cases from Shunyi B.1.470 group (25 [61.0%] male; median 40 age, 31 years [range, 27.5, 41.0]) had a statistically significant difference in median age 41 (P = 0.014). Seven clinical indicators of Daxing B.1.1.7 group were significantly higher 42 than Shunyi B.1.470 group including patients having fever over 38°C (14/33 [46.43%] 43 in Daxing B.1.1.7 group vs. 9/41 (21.95%) in Shunyi B.1.470 group [P = 0.015]), C-44

- reactive protein ([CRP, mg/L], 4.30 [2.45, 12.1] vs. 1.80, [0.85, 4.95], [P = 0.005]),
- 46 Serum amyloid A ([SAA, mg/L], 21.50 [12.50, 50.70] vs. 12.00 [5.20, 26.95], [P =
- 47 0.003]), Creatine Kinase ([CK, U/L]), 110.50 [53.15,152.40] vs. 70.40 [54.35,103.05],
- 48 [P = 0.040]), D-dimer ([DD, mg/L], 0.31 [0.20, 0.48] vs. 0.24 [0.17,0.31], [P = 0.038]),
- 49 CD4<sup>+</sup> T lymphocyte ([CD4<sup>+</sup> T, mg/L], [P = 0.003]), and Ground-glass opacity (GGO)
- in lung (15/33 [45.45%] vs. 5/41 [12.20%], [P = 0.001]). After adjusting for the age
- factor, B.1.1.7 variant infection was the risk factor for CRP (P = 0.045, Odds ratio [OR]
- 52 2.791, CI [1.025, 0.8610]), SAA (0.011, 5.031, [1.459, 17.354]), CK (0.034, 4.34, [0.05,
- 53 0.91]), CD4<sup>+</sup> T ( 0.029, 3.31, [1.13, 9.71]), and GGO (0.005, 5.418, [1.656, 17.729]) of
- patients. The median Ct value of RT-qPCR tests of the N-gene target in the Daxing
- B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P=0.036). The
- 56 phylogenetic analysis showed that only 2 amino acid mutations in spike protein were
- detected in B.1.470 strains while B.1.1.7 strains had 3 deletions and 7 mutations.
- Interpretation: Clinical features including a more serious inflammatory response,
- 59 pneumonia and a possible higher viral load were detected in the cases infected with
- 60 B.1.1.7 SARS-CoV-2 variant. It could therefore be inferred that the B.1.1.7 variant may
- 61 have increased pathogenicity.

- Funding: The study was funded by the National Key Research and Development
- Program (grant nos.2020YFC0846200 and 2020YFC0848300) and National Natural
- Science Foundation of China (grant no. 82072295).
- **Keywords:** COVID-19; SARS-CoV-2; B.1.1.7 Variant; clinical features; RT-qPCR test;

whole-genomic analysis

INTRODUCTION

67

68

69

79

80

81

82

83

84

85

86

87

88

89

Since December 2019, the coronavirus disease-19 (COVID-19) pandemic caused by the 70 highly infectious virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 71 has been rapidly spreading, which has posed a great threat to global public health<sup>1,2</sup>. 72 With the continuous transmission and mutation of SARS-CoV-2, some viral variants of 73 concern (VOC) and viriants of interest (VOI) have been reported in recent months<sup>3-8</sup>. 74 On December 14, 2020, the United Kingdom reported a SARS-CoV-2 variant of 75 concern (VOC) that belonged to the PANGO lineage B.1.1.79,10, referred to as "SARS-76 CoV-2 VOC-202012/01", "B.1.1.7", 501Y.V1 or 20I/501Y.V1 (the term B.1.1.7 was 77 used in the whole text). The B.1.1.7 variant was estimated to have emerged in late 78

September 2020 and has increased sharply to become the predominant SARS-CoV-2

strain in England, which has soon become a global concern<sup>7,11,12</sup>.

With the strict prevention and control policies implemented in China, local epidemics have rarely occurred in Beijing. Occasionally, a small clustered outbreak triggered by an imported SARS-CoV-2 strain with only one chain of transmission could happen. On January 17, 2021, a clustered COVID-19 outbreak in community had taken place in Daxing District, Beijing. Confirmed by whole-genome sequencing and lineage typing results<sup>9,10</sup>, this outbreak was caused by SARS-CoV-2 B.1.1.7 variants. This is the first local transmission of B.1.1.7 variants in China, which constituted a new challenge to the prevention and control of COVID-19 in China. Meanwhile, three weeks prior to the

90 Daxing outbreak, there was another local COVID-19 outbreak occurring in Shunyi

district in Beijing, caused by the B.1.470 lineage which was mostly detected in Asian

countries, both outbreaks had been well-controlled within a month.

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Since the early transmission of COVID-19 in January, 2020, a cohort of COVID-19

cases have been established in Beijing Ditan hospital; and since June, 2020, the COVID-

19 cases in Bejing have only been admitted to Ditan hospital, following which a cloud

database had been established and maintained by Ditan hospital cooperating with a

Beijing technology company (Beijing Zechuang Tiancheng Technology Development

Co., Ltd). All relevant data for COVID-19 cases are constantly being entered into the

cloud database for preparing for future prospective studies. So far, the data of about 690

cases were completely inputted. In this study, groups of two recent independent

clustered outbreaks caused by distinct lineage strains and occurring in different districts

in Beijing (Daxing B.1.1.7 group and Shunyi B.1.470 group) were selected as the study

subjects from the cloud database. The COVID-19 cases from the two groups received

alike clinical tests and treatments and each case was observed for at least 28 days. The

discharge criteria included disappearance or marked improvement of clinical symptoms

combined with two real-time reverse transcription quantitative PCR (RT-qPCR) tests

negative on nasopharyngeal swabs more than 24 hours apart, based on Diagnosis and

*Treatment Protocol for Novel Coronavirus Pneumonia Patients (Version 8).* 

Recent studies indicated that the B.1.1.7 variant has a 50% higher transmissibility<sup>13</sup>.

Fortunately, some immunological and serological studies indicated that the B.1.1.7 variant does not escape vaccine protection<sup>14,15</sup>. The UK government and related scientists suggested the B.1.1.7 variant may be more deadly, but currently there is no published biological experimental evidence regarding the virulence or pathogenicity of B.1.1.7<sup>16</sup>.

This study is aiming at comparing the clinical presentations, the RT-qPCR results and the whole-genomic features of cases from Daxing B.1.1.7 group and Shunyi B.1.470 group, in order to evaluate the COVID-19 severity of the cases infected by the B.1.1.7 variant.

#### **METHODS**

#### Study design and recruitment of cases

This prospective cohort study were reported according to the STROBE statement and included two groups with a total of 74 confirmed COVID-19 cases from Beijing Ditan Hospital, Daxing B.1.1.7 group and Shunyi B.1.470 group, based on the different Districts and genomic typing results. The data of all the cases from the two groups were extracted from the cloud database. The confirmed cases referred to patients with clinical features of COVID-19 and positive RT-qPCR test for SARS-CoV-2 RNA at least once on the respiratory specimens collected. The Daxing B.1.1.7 group contained a total of 33 cases whereas Shunyi B.1.470 group contained 41 cases. COVID-19 patients were diagnosed according to the 8th version of *Diagnosis and Treatment Protocol for Novel* 

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

Coronavirus Pneumonia Patients, and the clinical severity was categorized into 4 grades: mild (the clinical symptoms were mild, and there was no sign of pneumonia on imaging), moderate (showing fever and respiratory symptoms, imaging manifestations of pneumonia), severe (1. dyspnea with a respiratory rate >30/min; 2. hypoxemia with oxygen saturation <93%; 3. PaO2/FiO2 <300 mmHg; 4. or the clinical symptoms worsened gradually, and the lung imaging showed that the lesions progressed more than 50% within 24-48 hours) and critical (developed complications including 1. respiratory failure that needs mechanical ventilation; 2. shock; 3. patients with other organ failure need ICU monitoring treatment). The asymptomatic cases with no clinical symptoms but positive for RT-qPCR were also required to be admitted to the hospital. Ditan Hospital is affiliated with Capital Medical University, an academic tertiary care center in Beijing, China. The hospital is also a designated center in Beijing for the diagnosis and treatment of COVID-19. Each case was observed for at least 28 days. As of this study, four cases from Daxing outbreak and one case from Shunyi outbreak were still hospitalized.

The index case of the Shunyi B.1.470 group was an asymptomatic case confirmed on December 23, 2020. He intended to leave Beijing for taking an exam, so he took the initiative to conduct nucleic acid detection before leaving in accordance with the regulations. Further epidemiological investigation indicated that he was infected by an salesperson of a mall, and the salesperson was infected by an foreign personnel who was an imported asymptomatic case that had tested negative for SARS-CoV-2 RNA

within 14 days of entry. This was a clustered outbreak occurred mainly in workplaces in Shunyi District, with the majority of cases being young people. In addition, a family clustered infection including 7 members was detected.

The discovery of the index case of the Daxing B.1.1.7 group came from the routine screening of SARS-CoV-2 nucleic acid detection of a resident who intended to return home. The epidemiological investigation and nucleic acid detection of his close contacts indicated that a clustered outbreak had already occurred in the community where the case resided, of which most cases were elderly and children. Family clustered infection was mostly seen, involving a total of 13 families, of which 5 families were infected with more than 3 members and several families were infected with all members.

#### **Data collection**

The data of the 74 COVID-19 cases from the two groups were extracted from the cloud database. Medical record review was performed to collect patients' underlying medical conditions and symptoms at the time of diagnosis, including data of chronology of symptom onset, history of first presentation, disease progression, past medical history, physical findings, laboratory test results, imaging results, treatment and hospital course. In addition, epidemiological data of the patients were collected. Individual data were compiled into two groups of patients with the Daxing B.1.1.7 group and the Shunyi B.1.470 group for further analyses.

#### **Laboratory Testing**

The oropharyngeal swab, nasopharyngeal swab, or sputum specimens obtained from patients during their hospital stays were collected for RT-qPCR testing. Viral RNA was extracted directly from 200-µL swab samples with a QIAamp Viral RNA Mini Kit (QIAGEN, Germany). RT-qPCR was conducted using a commercial Novel SARS-CoV-2 Nucleic Acid Test Kit (BioGerm, Shanghai, China) with a fluorescence PCR detector following the manufacturers' instructions. A TaqMan probe—based kit was designed to detect the ORF1ab and N genes of SARS-CoV-2 in 1 reaction. Corresponding serum samples were tested for anti-SARS-CoV-2 antibodies using a chemiluminescence immunoassay (CLIA, Bioscience, Qingchong, China).

# Whole-genome sequencing and analysis

The selected swab samples of the patients were then sent to China CDC for further whole-genome sequencing. Libraries were prepared using a Nextera XT Library Prep Kit (Illumina, San Diego, CA, USA), and the resulting DNA libraries were sequenced on either a MiSeq or an iSeq platform (Illumina) using a 300-cycle reagent kit. Mapped assemblies were generated using the SARS-CoV-2 genome (accession number NC\_045512) as a reference. Variant calling, genome alignment, and sequence illustrations were generated with CLCBio software. The whole-genome sequence alignment was conducted using the Muscle tool in MEGA (v7.0). Neighbor-joining phylogenetic tree was constructed using the Kimura 2-parameter model with 1,000 bootstrap replicates. Genomic lineage designation was used "PANGO lineage" typing method (https://cov-lineages.org/).

Statistical analysis

The statistical analyses were performed using SPSS Version 24.0 (SPSS IBM, Armonk, NY, USA). We compiled data from each individual patient for the demography and clinical variables. Normal continuous variables were represented by mean and std, T-test was used to compare the statistical difference. Non-normal continuous variables were represented by median and quartile ranges, Mann-Whitney U test was used. Categorical variables were expressed as numbers and percentages, Chi-squared and Fisher's exact tests were used to compare the statistical difference. Binary logistic regression analysis was performed to analyze the risk factors for the severity of COVID-19. All tests were two-tailed, and statistical significance was defined as P value lower than 0.05.

## **Role of the funding source**

The study was funded by the National Key Research and Development Program (grant

nos. 2020YFC0846200 and 2020YFC0848300) and National Natural Science

Foundation of China (grant no. 82072295). The funding body was not involved in the

study design, clinical sample collection, data analysis, and interpretation or writing of

the manuscript.

#### **RESULTS**

Whole genome sequencing and analysis of the SARS-CoV-2 samples in the two

#### outbreaks

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Clinical samples from 8 patients of the Daxing outbreak, 13 patients of the Shunyi Outbreak were sent to the China CDC for further sequencing. Some samples may be degraded due to transportation or storage. Finally, a total of 9 whole-genome sequences with good quality and coverage were obtained, including 7 from the Daxing outbreak and 2 from the Shunyi outbreak. Compared with the Wuhan reference sequence (EPI ISL 402119), seven Daxing strains shared 31 nucleotide substitutions, six strains were identical, one had an addition substitution (32 substitutions) (Table 1). These seven strains shared all 28 nucleotide mutations that were first detected in the B.1.1.7 variant from the UK (Figure 2). Likewise, they had 3 amino acid deletions and 7 amino acid mutations on the spike protein corresponding to the characteristics of B.1.1.7 variants. The two strains of the Shunyi outbreak shared 24 nucleotide substitutions and one of them had an additional substitution (Table 1), which contained the single nucleotide polymorphisms (SNPs) defining PANGO lineage B.1.470 confirmed by Pangolin COVID-19 Lineage Assigner Web application<sup>9,10</sup> (https://pangolin.cog-uk.io/). This lineage is composed of only a hundred more sequences on the GISIAD database, most of which (77.0%) were from Indonesia. Strains from the GISAID database<sup>17</sup> which had high homology with these 2 strains were retrieved, including a Singaporean and an Indonesian strain that shared 21 and 20 nucleotide substitutions with the Shunyi strains, respectively (Figure 1).

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

Comparison of the general information and basic clinical manifestations in the two groups Of the 33 cases from the Daxing B.1.1.7 group and 41 from the Shunyi B.1.470 group (table1), male cases accounted for 45.50% and 61.00%, respectively. The median age of the two groups (39 years [interquartile range [IQR]30.50-62.50], vs. 31 years [IQR] 27.50-41.00]) showed a statistically significant difference (P =0.014). Moderate cases took up the highest percentage of both groups (66.67% vs. 48.78%). The most common symptoms in both groups were fever, followed by dry cough and dry throat/pharyngeal discomfort. Of patients infected with B.1.1.7 variant, 14 (46.43%) had fever over 38°C, significantly higher than 9 (21.95%) observed in patients infected with B.1.470 nonvariant (P = 0.015). Comparison of laboratory tests, imageological diagnosis and treatment measures There were no significant differences in the levels of white blood cells, neutrophils, lymphocytes, platelets, Alanine and Aspartate aminotransferases in the two groups (Table 2). However, the level of C-reactive protein (CRP), serum amyloid A(SAA),

lymphocytes, platelets, Alanine and Aspartate aminotransferases in the two groups (Table 2). However, the level of C-reactive protein (CRP), serum amyloid A(SAA), creatine kinase (CK), and D-dimer (DD) in the Daxing B.1.1.7 group was significantly higher than the Shunyi B.1.470 group (P =0.005, 0.003, 0.040 and 0.038, respectively). In addition, except for 1 case in the Daxing B.1.1.7 group and 2 cases in the Shunyi B.1.470 group who did not tested for T lymphocyte due to their young age, the abnormal proportion of CD4<sup>+</sup> T lymphocytes(CD4<sup>+</sup>T) in the Daxing B.1.1.7 group was significantly higher than the Shunyi B.1.470 group (P=0.003). For the imageological

diagnosis, there were no significant differences in the incidence of pneumonia, but the Ground-glass opacity (GGO) observed in the B.1.1.7-variant patients was significantly higher (P =0.001). The antibody detection results and clinical treatments were not statistically different in the two groups.

#### B.1.1.7 variant infection was the main risk for more serious COVID-19 clinical

#### features

267

268

269

270

271

272

273

281

282

283

284

285

286

287

288

In order to avoid the influence of older age in the Daxing B.1.1.7 group, binary logistic regression analysis was further performed for investigating the level of CRP (<7mg/L or  $\ge 7$  mg/L), SAA (<10mg/L or  $\ge 10$  mg/L), CK (<150U/L or  $\ge 150U/L$ ), DD (<0.5mg/L or  $\ge 0.5mg/L$ ), CD4<sup>+</sup> T (<706mg/L or  $\ge 706mg/L$ ) and GGO in the lung (Table 3). After adjusting for age factor, we found that the group factor (B.1.1.7 variant infection or non-variant infection) was the main risk for CRP (Odds ratio [OR] =2.79, P =0.045), SAA (OR =5.03, P =0.011), CK (OR = 0.22, P =0.034), GGO (OR=5.42,

#### Comparison of RT-qPCR threshold-crossing (Ct) values between the two groups

P=0.005), and CD4<sup>+</sup> T(OR=3.31, P=0.029) of patients.

During the hospitalization of all the cases, several RT-qPCR tests using nasopharyngeal swabs were regularly conducted based on their disease progression and clinical manifestations. The lowest Ct value of ORF1ab and N gene of each case was selected and compared between the two groups (Table 4). The Kits for RT-qPCR testing had uniform lot number and the instrument was the same. The median Ct value of ORF1ab-

gene target in the two groups had no statistically significant difference, but that of N-gene target was significantly lower for the Daxing B.1.1.7 group than the Shunyi B.1.470 group (t=2.139, P=0.036). The distribution of the samples in the two groups was compared within all ORF1ab and N-gene Ct values (Figure 1). Figure 1b indicates that in N-gene, the median Ct values of the Daxing B.1.1.7 group were lower. In addition, we also adjusted the age factor and performed binary logistic regression analysis for the level of Ct values (>18 or  $\le 18$ ) (Table 5). Similarly, patients infected with the B.1.1.7 variant had a 4.484-fold higher risk of having N gene Ct values  $\le 18$  in nasopharyngeal swab specimens than the patients infected with non-variant (OR=4.484, P=0.024).

#### **DISCUSSION**

Researches have commonly indicated that the SARS-CoV-2 B.1.1.7 variant had higher transmissibility while whether it had increased pathogenicity remained controversial. In this study, we analyzed the differences of clinical characteristics, laboratory tests, RT-qPCR results and whole-genome features between the 33 cases infected with SARS-CoV-2 B.1.1.7 variant and 41 cases infected with non-variant, and indicated that COVID-19 cases infected with the B.1.1.7 variant had more serious clinical features and possibly higher viral loads. This therefore implies that the B.1.1.7 variant may have increased pathogenicity.

In the Daxing B.1.1.7 group, we observed an older age of patients than the Shunyi B.1.470 group, probably due to the living characteristics of residents from the

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

community, as many retired older people were more frequently active in the community. B.1.1.7 variant infection could lead to a more serious inflammatory response, acute response process and more severe pneumonia as indicated by the following results: compared B.1.1.7 variant cases with non-variant cases, (1) there were more patients with body temperature over 38°C; (2) the laboratory tests of the level of CRP, SAA, CK and DD was significantly higher; (3) the abnormal proportion of CD4<sup>+</sup>T was significantly higher; (4) the patients that had ground glass opacity in the lung were significantly more. When comparing the Ct values of the RT-qPCR results between the two groups, samples from the Daxing B.1.1.7 group were related to lower Ct values of N gene, from which it could be speculated that B.1.1.7 variant samples may have a relatively higher viral load. This result corresponded with previous research showing that the B.1.1.7 variant is associated with significantly higher viral loads in samples tested by ThermoFisher TagPath RT-qPCR<sup>18</sup>. Even though the sample size in this study was relatively small, and no significant difference was detected in ORF gene, statistical results for N gene could still somehow indicate a higher infectivity of the B.1.1.7 variant. SARS-CoV-2 B.1.1.7 variant infection may be the main risk for more serious clinical features after adjusting the age factor. Old-age has been considered as an important factor in SARS-CoV-2 infection and severe COVID-19, because elderly patients have a

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

weaker immune system function and are prone to multi-system organ dysfunction and even failure<sup>19-22</sup>. Thus, we adjusted the effect of older age of the Daxing B.1.1.7 group, and still came to the consistent statistically significant results that cases infected with the B.1.1.7 variant presented more serious clinical features and higher infectivity. The phylogenetic analysis showed that the strains from the two groups belonged to different lineages. The whole genomic analysis revealed that the case samples from group-DX B.1.1.7 had 3-4 specific substitutions in addition to the 28 nucleotide substitutions corresponding to the B.1.1.7 reference sequence, which indicated that the strains might have been evolving for some time and transmitted to China. The retrieving result of the sequences that had the highest similarity with the strains of the Shunyi B.1.470 group might somehow indicate potential countries of origin. Furthermore, only two amino acid mutations in the S protein were detected in the strains from the Shunyi outbreak, which suggested lower transmissibility compared with B.1.1.7 strains. The interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the ACE2 receptor on host cells is vital for viral entry and the N501Y amino acid mutation of B.1.1.7 in RBD of the interface should be favorable for the interaction with ACE2<sup>14,23,24</sup>. Therefore, N501Y mutation likely increased transmissibility and possibly pathogenicity of B.1.1.7. Other studies indicated that the deletion of 69-70 amino acids on S1 N-terminal domain could enhance virulence and confer resistance to the neutralization antibody of SARS-CoV-2<sup>25</sup>. Fortunately, many recent studies on the

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

protection of existing vaccines against B.1.1.7 variants all indicated that the B.1.1.7 variant will not escape vaccine protection <sup>14,15,23,24</sup>. Nevertheless, currently there is no direct biological experimental evidence that can confirm the increased pathogenicity or virulence of the B.1.1.7 variant and little evaluation of the clinical characteristics of B.1.1.7 variant infection have been conducted. This prospective, comparative cohort study of COVID-19 cases from two COVID-19 outbreaks in Beijing implied that COVID-19 cases led by the B.1.1.7 variant presented more serious clinical and laboratory characteristics than cases infected with non-B.1.1.7 variant (lineage B.1.470). Limitations of this study exist. Firstly, due to the very low morbidity of COVID-19 now in China, the sample size in the two groups of this study was relatively small; secondly, we were not able to compare the clinical features of the cases infected with the B.1.1.7 variant with the cases infected with other SARS-CoV-2 lineages other than B.1.470. Because during December, 2020 – January 2021, only these two clustered outbreaks had taken place in Beijing, the data of these two groups was more comparable. **Contributors** ZC conceived the study; ZC, WX and WZ designed the study; ZC and WZ maintained database for data collection; ZC, WX and WZ supervised the data collection; WZ, SC, ZG, DT, YS, GW, XW, YW, PX, YX, TZ, LL, GL and JT interpreted the data; SC, ZG

and GW did the statistical analysis; YS, WZ, SC and ZG wrote the manuscript; YS and SC prepared the figures; YS, XZ, SZ and YW did the COVID-19 specimens processing and sequencing; All authors reviewed and approved the final version of the manuscript. ZC, WZ and WX are the guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

### Acknowledgments

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

We thank all physicians who participated in the management of these COVID-19 cases.

The study was funded by the National Key Research and Development Program (grant

nos. 2020YFC0846200 and 2020YFC0848300) and National Natural Science

Foundation of China (grant no. 82072295). The funding body was not involved in the

study design, clinical sample collection, data analysis, and interpretation or writing of

the manuscript.

#### **Declaration of interest**

The authors declare that no competing interests exist.

#### **Data sharing**

The data that support the findings of this study are available from the corresponding author on reasonable request. Participant data without names and identifiers may be shared with other researchers after approval from the corresponding author and the

authorities including the Institutional Review Board and the National Health Commission. The proposal with a detailed description of study objectives and a statistical analysis plan will be needed for evaluation of the reasonability to request for our data. The corresponding author will make a decision based on these materials. Following complete publication, the sequence data generated in this study was made available to researchers through GISAID database (accession nos: EPI\_ISL\_1121993 and EPI\_ISL\_1122015 to 1122017).

#### **Ethical approval**

399

400

401

402

403

404

405

406

407

410

411

412

413

- The study was approved by the Institutional Review Board of Beijing Ditan Hospital,
- Capital Medical University in Beijing (approval number: JDLY2020-020-01).

#### References

- 414 1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected
- 415 Pneumonia in Wuhan, China. JAMA 2020; **323**(11): 1061-9.
- 416 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med
- 417 2020; **382**(8): 727-33.
- 418 3. Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities.
- 419 JAMA 2021.
- 420 4. Tada T, Dcosta BM, Samanovic-Golden M, et al. Neutralization of viruses with European, South African, and United
- 421 States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv
- 422 2021.
- 423 5. Fujino T, Nomoto H, Kutsuna S, et al. Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan. Emerg
- 424 Infect Dis 2021; 27(4).
- 425 6. Dao MH, Nguyen HT, Nguyen TV, et al. New SARS-CoV-2 Variant of Concern Imported from the United Kingdom to
- 426 Vietnam, December 2020. J Med Virol 2021.
- 427 7. Brookman S, Cook J, Zucherman M, Broughton S, Harman K, Gupta A. Effect of the new SARS-CoV-2 variant B.1.1.7

- on children and young people. Lancet Child Adolesc Health 2021.
- 429 8. Mwenda M, Saasa N, Sinyange N, et al. Detection of B.1.351 SARS-CoV-2 Variant Strain Zambia, December 2020.
- 430 *MMWR Morb Mortal Wkly Rep* 2021; **70**(8): 280-2.
- 431 9. Rambaut A, Holmes EC, O'Toole A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
- 432 epidemiology. *Nat Microbiol* 2020; **5**(11): 1403-7.
- 433 10. Rambaut A, Holmes EC, O'Toole A, et al. Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to
- assist genomic epidemiology. *Nat Microbiol* 2021; **6**(3): 415.
- 435 11. Alpert T, Lasek-Nesselquist E, Brito AF, et al. Early introductions and community transmission of SARS-CoV-2 variant
- 436 B.1.1.7 in the United States. *medRxiv* 2021.
- 437 12. Eurosurveillance editorial t. Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-
- 438 CoV-2 variants of concern in the EU/EEA first update. Euro Surveill 2021; 26(3).
- 439 13. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of
- 440 Concern 202012/01 in England. *medRxiv* 2021.
- 441 14. Graham C, Seow J, Huettner I, et al. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing
- diverse epitopes on SARS-CoV-2 Spike. bioRxiv 2021.
- 443 15. Muik A, Wallisch AK, Sanger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-
- 444 elicited human sera. Science 2021.
- 445 16. Peter Horby CH, Nick Davies, John, Edmunds, Neil Ferguson, Graham Medley, Andrew Hayward, Muge Cevik, Calum
- Semple. NERVTAG note on B.1.1.7 severity. In: SAGE, editor.; 2021.
- 447 17. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to reality. Euro Surveill 2017;
- 448 **22**(13).
- 449 18. Kidd M, Richter A, Best A, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads
- in samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis 2021.
- 451 19. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-
- 452 aged patients. J Infect 2020; **80**(6): e14-e8.
- 453 20. Han W, Zhu M, Chen J, et al. Lung Transplantation for Elderly Patients With End-Stage COVID-19 Pneumonia. Ann
- 454 Surg 2020; **272**(1): e33-e4.
- 455 21. Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly. Lancet Public Health 2020; 5(5):
- 456 e256.

465

466

- 457 22. Petretto DR, Pili R. Ageing and COVID-19: What is the Role for Elderly People? Geriatrics (Basel) 2020; 5(2).
- 458 23. Firestone MJ, Lorentz AJ, Wang X, et al. First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota December
- 459 2020-January 2021. MMWR Morb Mortal Wkly Rep 2021; 70(8): 278-9.
- 460 24. Edara VV, Floyd K, Lai L, et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
- 461 medRxiv 2021.
- 462 25. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2
- 463 vaccine-elicited sera. Nat Med 2021.

# **Tables**

Table 1. Comparison of the whole-genome features between the two groups

Features	Daxing B.1.1.7 group	Shunyi B.1.470 group		
No. of sequences	7	2		
PANGO lineage	B.1.1.7	B.1.470		
VOC or not	VOC-202012/01	non-VOC		
No. of shared nucleotide substitutions	31	24		
	C241T, C913T, C3037T, C3267T,			
	C5388A, C5986T, T6954C, C12036G,	C241T, C1454G, C3037T, T6778C,		
	C12747T, C12970T, C14408T,	C9679T, G11291A, T11296G,		
Shared nucleotide	C14676T, C15279T, T16176C,	C14120T, C14408T, C17421T,		
substitution sites	A23063T, C23271A, A23403G,	G18315A, C18687T, C18877T,		
(ref. Wuhan-Hu-1,	C23604A, C23709T, T24506G,	C21597T, A23403G, G25563T,		
EPI_ISL_ 402119)	G24914C, C27972T, G28048T,	G25855C, G26051T, C26681T,		
	A28111G, G28280C, A28281T,	C26735T, G27870T, C27903T,		
	T28282A, G28881A, G28882A,	C28887T, C29311T		
	G28883C, C28977T			
Additional substitution site	T21991G	T20246G		
A	H69-V70del, Y144del			
Amino acid mutations on	N501Y, A570D, D614G, P681H,	S12F, D614G		
Spike protein	T716I, S982A, D1118H			

Table 2. Comparison of the general situation and clinical manifestations between the

483

two groups

Variable	Daxing B.1.1.7 group	Shunyi B.1.470 group	<b>P value</b> 0.183	
	(n = 33)	(n=41)		
Male [n, (%)]	15 (45.50)	25 (61.00)		
Age	39.00 (30.50, 62.50)	31.00 (27.50, 41.00)	0.014	
Days from onset to admission	1.00 (1.00, 2.00)	1.00 (1.00, 3.00)	0.133	
Body Mass Index	23.11 (20.84, 25.08)	22.48 (20.45, 25.57)	0.898	
Clinical severity level [n, (%)]				
Asymptomatic	4(12.12)	8 (19.51)	0.391	
Mild	7 (21.21)	13 (31.70)	0.312	
Moderate	22 (66.67)	20 (48.78)	0.123	
Severe	0 (0.00)	0 (0.00)	-	
Critical	0 (0.00)	0 (0.00)	-	
Underlying disease [n, (%)]	13 (39.39)	14 (34.15)	0.641	
Hypertension	3 (9.09)	6 (14.63)	0.723	
Diabetes	2 (6.06)	3 (7.32)	> 0.999	
Clinical manifestations [n, (%)]				
Fever	19 (57.58)	19 (46.34)	0.337	
Temperature ≥ 38°C	14 (46.43)	9 (21.95)	0.015	
Intolerance of cold	2 (6.06)	0 (0.00)	0.195	
Dry cough	14 (42.42)	17 (41.46)	0.934	
Expectoration	5 (15.15)	4 (9.76)	0.361	
Nasal congestion	4 (12.12)	2 (4.88)	0.397	
Runny nose	1 (3.03)	2 (4.88)	> 0.999	
Hyposmia	1 (3.03)	1 (2.44)	> 0.999	
Hypogeusia	0 (0.00)	1 (2.44)	> 0.999	
Dry throat/pharyngeal discomfort	6 (18.18)	16 (39.02)	0.051	
Sore throat	4 (12.12)	3 (7.32)	0.693	
Headache	1 (3.03)	3 (7.32)	0.624	
Asthenia	5 (15.15)	1 (2.44)	0.083	
Dizziness	2 (6.06)	0 (0.00)	0.195	
Muscle soreness	3 (9.09)	3 (7.32)	> 0.999	
Joint pain	1 (3.03)	0 (0.00)	0.446	
Shortness of breath	0 (0.00)	0 (0.00)	> 0.999	
Dyspnea	0 (0.00)	0 (0.00)	> 0.999	
Chest tightness	2 (6.06)	2 (4.88)	> 0.999	
Chest pain	0 (0.00)	0 (0.00)	> 0.999	
Conjunctival hyperemia	0 (0.00)	0 (0.00)	> 0.999	
Nausea	0 (0.00)	2 (4.88)	0.499	
Vomiting	0 (0.00)	0 (0.00)	> 0.999	
Diarrhea	1 (3.03)	2 (4.88)	> 0.999	

Abdominal pain 0 (0.00) 0 (0.00) > 0.999

484

485

Table 3. Comparison of laboratory tests, CT results and treatment measures

1	<b>,</b>			
Variable	Daxing B.1.1.7 group	Shunyi B.1.470 group	P value	
	(n = 33)	(n = 41)		
Laboratory tests				
White blood cell count(×10 <sup>9</sup> /L)	5.16 (4.32, 7.15)	5.69 (4.49, 7.02)	0.628	
Neutrophil count (×10 <sup>9</sup> /L)	3.23 (2.60, 4.55)	3.45 (2.44, 4.64)	0.948	
Neutrophil percentage (%)	65.30 (54.42, 71.25)	62.30 (56.90, 72.96)	0.786	
Lymphocyte count (×10 <sup>9</sup> /L)	1.42 (0.93, 1.91)	1.39 (0.91, 1.82)	0.996	
Lymphocyte percentage (%)	23.44 (19.25, 34.25)	27.40 (18.02, 35.05)	0.732	
Platelet count(×10 <sup>9</sup> /L)	223.00 (185.00, 262.50)	217.40 (181.50, 269.00)	0.716	
C-reactive protein (mg/L)	4.30 (2.45, 12.15)	1.80, (0.85, 4.95)	0.005	
Serum amyloid A (mg/L)	21.50 (12.50, 50.70)	12.00 (5.20, 26.95)	0.003	
Alanine aminotransferase (U/L)	16.60 (11.15, 28.50)	21.00 (12.55, 37.80)	0.370	
Aspartate aminotransferase (U/L)	26.30 (18.90, 34.15)	23.20 (17.85, 29.45)	0.236	
Lactic Dehydrogenase (U/L)	187.50 (170.05, 228.15)	194.90 (174.25,224.80)	0.708	
Creatine Kinase (U/L)	110.50 (53.15,152.40)	70.40 (54.35,103.05)	0.040	
Prothrombin Time (s)	12.20 (11.60,12.70)	12.20 (11.45,12.80)	0.947	
Activated partial thromboplastin	33.50 (30.80,35.10)	31.75 (29.50,34.35)	0.257	
Time (s)				
D-dimer (mg/L)	0.31 (0.20, 0.48)	0.24 (0.17, 0.31)	0.038	
Г lymphocyte (cells/uL)				
<1027	14.00 (43.75)	21.00 (53.85)	0.397	
≥1027	18.00 (56.25)	18.00 (46.15)		
CD4 <sup>+</sup> T lymphocyte (cells/uL)			0.003	
< 706	21.00 (65.63)	12.00 (30.77)		
≥706	11.00 (34.38) 27.00 (69.23)			
CD8 <sup>+</sup> T lymphocyte (cells/uL)				
<320	15.00 (46.88)	17.00 (43.60)	0.782	
≥320	17.00 (53.13)	22.00 (56.41)		
Imaging examination [n, (%)]				
Pneumonia unilateral	10.00 (30.30)	15.00 (36.59)	0.570	
Pneumonia	15.00 (45.45)	11.00 (26.83)	0.095	
Ground glass opacity	15.00 (45.45)	5.00 (12.20)	0.001	
Antibody detection [n, (%)]				
IgM (+)	1.00 (3.03)	2.00 (4.88)	> 0.999	
IgG (+)	1.00 (3.03)	3.00 (7.32)	> 0.999	
Treatments [n, (%)]				
Favelavir	7.00 (21.21)	4.00 (9.76)	0.295	

Favelavir + Abidol	1.00 (3.03)	4.00 (9.76)	0.373
Interferon	1.00 (3.03)	1.00 (2.44)	> 0.999
Traditional Chinese medicine	23.00 (69.70)	27.00 (65.85)	0.726
Oxygen inhalation	5.00 (15.15)	8.00 (19.51)	0.624

**Table 4.** Risk of CRP, SAA and GGO of patients upon variant (B.1.1.7 variant infection or non-variant infection)

Outcomes	Variables	Regression	Standard	Wald Chisq	P	Odds ratio	95% CI for
Outcomes		coefficient	error	Value	value	Odds ratio	OR
Level of CRP	Age	0.00	0.01	0.03	0.854	1.00	[0.98, 1.03]
$(<7$ mg/L or $\ge$ 7	Cassa	1.09	0.54	4.02	0.045	2.79	[1.03, 0.86]
mg/L)	Group						
Level of SAA	Age	0.03	0.02	2.63	0.105	1.03	[0.99, 1.06]
$(\leq 10 \text{mg/L or} \geq 10$	Cassa	1.62	0.63	6.54	0.011	5.03	[1.45, 17.35]
mg/L)	Group						
Had GGO or not	Age	0.01	0.02	0.69	0.408	1.01	[0.98, 1.04]
Had GGO of not	Group	1.69	0.61	7.80	0.005	5.42	[1.66, 17.73]
Level of CK	A	0.00	0.02	0.05	0.921	1.00	[0.07, 1.04]
(<150U/L  or	Age	0.00	0.02	0.05	0.821	1.00	[0.97, 1.04]
≥150U/L)	Group	-1.52	0.73	4.34	0.034	0.22	[0.05, 0.91]
Level of DD	<b>A</b>	0.06	0.02	C 1.4	0.012	1.07	[1 01 1 12]
(<0.5mg/L or	Age	0.06	0.03	6.14	0.013	1.07	[1.01, 1.12]
$\geq$ 0.5mg/L)	Group	0.70	0.82	0.73	0.392	2.01	[0.41, 10.02]
Level of CD4 <sup>+</sup> T	Α	0.05	0.02	7.55	0.006	1.05	[1.01. 1.00]
(<706cells/uL or	Age	0.05	0.02	7.55	0.006	1.05	[1.01, 1.08]
≥706cells/uL)	Group	1.20	0.55	4.77	0.029	3.31	[1.13, 9.71]

**Table 5.** Compared lowest RT-qPCR Ct values in two groups

Lowest Ct values	Daxing B.1.1.7 group	Shunyi B.1.470 group	P value
	(n=33)	(n=41)	
ORF1ab (Mean ± SD*)	$23.33 \pm 4.24$	$24.31 \pm 5.21$	0.417
$N (Mean \pm SD)$	$20.58 \pm 4.34$	$23.22 \pm 5.37$	0.036

<sup>\*</sup>SD, Standard Deviation

# **Table 6.** Risk of Ct values of N gene-target of patients upon variant (B.1.1.7 variant infection or non-variant infection)

Variables	Regression	Standard	Wald Chisq	P value	Odds	95% CI for OR
	coefficient	error	Value		ratio	
Age	-0.01	0.02	0.42	0.518	0.99	[0.96, 1.02]
Group	1.50	0.67	5.08	0.024	4.48	[1.22, 16.53]

# Figures and Figure legends





Figure 1. Neighbor-Joining phylogenetic tree based on the whole genome sequences of the SARS-CoV-2 representative strains. The two representative strains from the Daxing B.1.1.7 group were indicated by deep blue dots, font and a left arrow; while the strains from the Shunyi B.1.470 group were indicated by red dots, font and a left arrow. Strains associated with other previous outbreaks in China were indicated with ice blue triangles. The B.1.1.7 and B.1.470 lineage was highlighted with blue and light red background, respectively, the two strains that shared high homology with the strains of the Shunyi B.1.470 group were colored in purple font. The Wuhan reference strain was shaded in gray. The PANGO lineages were marked and colored on the right. The tree was rooted using strain WH04 (EPI ISL 406801) in accord with the root of Pangolin tree.



**Figure 2.** Scatter plot of the RT-qPCR Ct values of the Daxing B.1.1.7 group and the Shunyi B.1.470 group. (A) Ct values of OFR1ab-gene target; (B) Ct values of N-gene target. Samples from the Daxing B.1.1.7 group were shown as red dots while from the Shunyi B.1.470 group as blue dots. Median Ct was indicated by a black horizon bar.